Mandate

Vinge advises on equity line and rights issue guarantee to Karo Bio

October 27, 2010

Azimuth Opportunity, Inc and Karo Bio AB (publ) (NASDAQ OMX Stockholm) have entered an agreement regarding a so-called Equity Credit Facility, whereby Azimuth has undertaken to subscribe for new shares in Karo Bio on Karo Bio’s request and as set out in the terms of the facility, of up to USD 35 million. In addition, Azimuth guarantees part of Karo Bio’s rights issue of approx. SEK 300 million. The Facility and the rights issue are subject to approval by the general meeting of Karo Bio.

Vinge advises Azimuth. Vinge’s team is headed by capital markets partner Erik Sjöman.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026